Sajarah

"Bali menyang Pipa

Prestasi kita:

Sorrento wis lelampahan dawa saka wiwitan andhap asor kanggo biopharma macem-macem nemokake lan ngembangaken medicine ngganti urip.

2009

Founded

2013

Angsal aset Resiniferatoxin (RTX) liwat akuisisi Sherrington Pharmaceuticals Inc.
Acquired Antibody Drug Conjugation (ADC) teknologi liwat akuisisi Concortis Biosystems Corp.

2014

PD-L1 sing ora dilisensi kanggo pasar Greater China menyang Lee's Pharm

2016

Kawangun ImmuneOncia JV karo Yuhan Pharmaceuticals
Angsal ZTlido® liwat saham mayoritas ing Scilex Pharmaceuticals
Angsal Bioserv Corporation kanggo operasi manufaktur cGMP
Dibentuk Levena Suzhou Biopharma Co. LTD kanggo layanan Konjugasi Obat Antibodi (ADC).

2017

Angsal platform Virus Oncolytic liwat akuisisi Virttu Biologics Limited
Kawangun Celularity karo Celgene lan United Therapeutics

2018

Angsal Sofusa® Sistem Pangiriman Limfatik saka Kimberly-Clark

2019

Angsal Semnur Pharmaceuticals
Nggawe Scilex Holding kanggo nggabungake penggabungan Scilex Pharma lan Semnur Pharma

2020

Abivertinib sing dilisensi eksklusif saka ACEA Therapeutics kanggo kabeh indikasi ing saindenging jagad, ora kalebu China
Platform diagnostik HP-LAMP sing dilisensi eksklusif saka Universitas Columbia kanggo ndeteksi coronavirus lan virus influenza
Angsal SmartPharm Therapeutics

2021

Acquired ACEA Therapeutics

2022

Angsal Virexhealth